Skip to main content
PMC home page
Oncology Letters logoLink to Oncology Letters
. 2017 Jul 8;14(3):3043–3050. doi: 10.3892/ol.2017.6556

Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL-60 cells

Huicong Yang 1, Yiqun Huang 2, Yong Zou 2, Xudong Ma 2,✉
PMCID: PMC5588084  PMID: 28927052

Abstract

The aim of the present study was to investigate the synergistic effect of phenylhexyl isothiocyanate (PHI) and LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] on the PI3K/protein kinase B (Akt) signaling pathway, modulating histone acetylation, inhibiting cell viability and inducing apoptosis in HL-60 cells. The inhibition of HL-60 cell viability was monitored using an MTT assay. Cell apoptosis was measured using flow cytometry. Expression of acetylated histone H3 and histone H4, and the Akt signaling pathway proteins phosphorylated Akt (p-Akt), phosphorylated mammalian target of rapamycin (p-mTOR) and phosphorylated ribosomal protein S6 kinase (p-p70S6K) was detected using western blotting. The results of the present study identified that PHI and LY294002 were able to inhibit cell viability and induce cell apoptosis in HL-60 cells. The combination exhibited a synergistic effect on cell viability and apoptosis. PHI treatment led to an accumulation of acetylated histone H3 and histone H4, but LY294002 treatment had no effect on histone acetylation. However, LY294002 was identified to enhance the effect of PHI on histone acetylation in HL-60 cells. PHI and/or LY294002 were identified to dephosphorylate proteins in the PI3K/Akt signaling pathway, with a synergistic effect observed when used in combination. The results of the present study indicated that the combination of PHI and LY294002 may offer a novel therapeutic strategy for acute myeloid leukemia.

Keywords: phenylhexyl isothiocyanate, LY294002, phosphoinositide 3-kinase/protein kinase B, acetylation, apoptosis

Introduction

Acute myeloid leukemia (AML) is a heterogeneous group of malignant hematopoietic disorders characterized by uncontrolled proliferation of clonally neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program which are inhibited at various maturation steps and are resistant to cell death (1). Intensification of chemotherapy has resulted in remission in between 70 and 85% of patients with AML; however, post-remission relapses occur frequently (2,3).

The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway is a key mediator of cell viability, proliferation and apoptosis. Its constitutive activation has been implicated in the pathogenesis and progression of a variety of neoplasias (4). The PI3K/Akt axis is activated in AML (5–8). The disease-free survival and overall survival times have been demonstrated to be significantly decreased in cases of AML with upregulated PI3K/Akt signaling pathway protein expression (9). The PI3K/Akt signaling pathway is crucial to diverse physiological processes that include cell cycle progression, differentiation, transcription, translation and apoptosis (10,11). The PI3K/Akt signaling pathway is targeted for genomic aberrations including amplification, mutation and rearrangement more frequently than any other signaling pathway in human cancer, with the possible exception of the p53 and retinoblastoma signaling pathways. There is convincing evidence that the alterations of the PI3K/Akt signaling pathway are associated with tumor progression and resistance to radiation and systemic therapies in humans (12,13). LY294002 is an inhibitor of PI3K, which has been used extensively to investigate the role of the PI3K/Akt signaling pathway in normal and transformed cells (14,15). Inactivation of PI3K using LY294002 has been demonstrated to lead to the dephosphorylation of Akt at Thr308 and Ser473, consequently inducing specific G1 phase arrest in cell proliferation and finally to apoptosis (16,17). PI3K inhibitors also exhibit antitumor activity in vitro and in vivo in a variety of tumor types (18–20). Therefore, in the present study, it was investigated whether LY294002 was able to increase the sensitivity of AML cells to PHI.

Isothiocyanates are naturally sourced compounds typically isolated from plants of the Brassicaceae family, including broccoli, cabbage, and radish. Isothiocyanates are best known for their antioxidative, anticancer chemotherapeutic, chemopreventive, and anti-angiogenic properties (21,22). PHI, a synthetic isothiocyanate, is able to induce cell growth arrest and apoptosis in a number of types of tumor cell by inhibiting histone deacetylation, histone methylation and DNA methylation, and by remodeling chromatins (23–27).

In the present study, the rationale for the combined inhibition of PHI and LY294002 in HL-60 cells was investigated. Although the effect of LY294002 or PHI has been identified in a number of types of human cancer, the synergistic effect of PHI and LY294002 remains unclear.

Materials and methods

Reagents

PHI (LKT Laboratories, Inc., St. Paul, MN, USA), >98% pure, was dissolved in 75% methanol to a stock concentration of 5 mmol/l and stored at −20°C following positive pressure filtration through a 0.22 µmol/l microporous membrane filter. LY294002 (Cell Signaling Technology, Inc., Danvers, MA, USA), >99% pure, was dissolved in dimethyl sulfoxide (DMSO) to a stock concentration of 5 mmol/l. Antibodies against acetyl-histone H3 (cat. no., 06-599) and acetyl-histone H4 (cat. no., 06-866) were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). Antibodies against p-Akt (cat. no., 12694), p-mTOR (cat. no., 5536) and p-p70S6K (cat. no., 9208) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). β-actin antibody (cat. no., sc-47778), goat anti-rabbit IgG-HRP (cat. no., sc-2004) and goat anti-mouse IgG-HRP (cat. no., sc-2005) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). MTT (Sigma; Merck KGaA, Darmstadt, Germany) was dissolved in PBS to a working concentration of 5 mmol/l.

Cell culture

The human AML cell line HL-60 was obtained from the China Center for Type Culture Collection (Beijing, China). Cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (both were obtained from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and maintained at 37°C in a humidified atmosphere containing 5% CO2. Cells in exponential growth phase were exposed to PHI and/or LY294002 at various concentrations, as indicated for each assay. The control cultures were supplemented with the methanol-containing medium and DMSO-containing medium respectively.

Cell viability assay

MTT assay was used to analyze cell viability as described previously (28). The spectrophotometric absorbance of the samples was determined using an Ultra Multifunctional microplate reader at 490 nm. Cells in exponential growth phase (1.0×105 cells/ml in 100 µl) were cultured in 96-well plates with various concentrations of PHI and LY294002 (0, 10, 20 and 40 µmol/l, respectively, or in combination at 20 µmol/l each). Cell viability was observed at 24, 48, 72 and 96 h. The assay was conducted in triplicate. For evaluating the synergistic effects of the drugs, HL-60 cells were treated with 10, 15, 20, 30 and 40 µmol/l PHI, and 10, 15, 20, 30 and 40 µmol/l LY294002 for 72 h.

Analysis of cell apoptosis using flow cytometry

HL-60 cells were seeded at 5.0×105 cells/ml in Petri dishes and cultured with the aforementioned concentrations of PHI or LY294002, or in combination, for 72 h. An annexin V-fluorescein isothiocyanate (FITC)/PI double-fluorescence apoptosis detection kit (Kaiji Biotech, Nanjing, China) was employed to quantify the apoptosis of the HL-60 cells, according to the manufacturer's protocol. Briefly, the suspended cells were pooled, washed twice with ice-cold PBS and re-suspended in binding buffer (Kaiji Biotech, Nanjing, China) to 106/ml. Subsequently, 0.2 ml of this cell suspension was incubated with 5 µl Annexin V-FITC and 5 µl PI Staining Solution for 10 min at room temperature in the dark. Then, samples were analyzed using a flow cytometer (BD FACSCaliburTM, San Jose, CA, USA) within 1 h. The experiment was performed in triplicate.

Western blot analysis

The protein levels were established by Western blot analysis as described previously (29). Total proteins were prepared from each culture condition with a lysis buffer containing protease inhibitors, and the lysed solution was centrifuged at 13,000 × g for 20 min at 4°C. The protein content of the lysates was determined using the Bradford protein assay. Equivalent amounts of protein (20 µg) were separated were subjected to 12% SDS-PAGE and then electrotransferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). The membranes were blocked in PBS containing 5% w/v skimmed dry milk at room temperature for 1 h, and then incubated at 4°C overnight with the following antibodies: Acetyl-histone H3, acetyl-histone H4, p-Akt, p-mTOR and p-p70S6K at the recommended dilution (1:500). Additionally, the membranes were incubated with HRP-conjugated goat anti-mouse (1:5,000) or goat anti-rabbit secondary antibodies (1:5,000) at room temperature for 1 h. Finally, the membranes were exposed to X-ray film following use of enhanced chemiluminescence reagents (Cell Signaling Technology). Protein levels were quantified relative to β-actin as a loading control by using Image-Pro Plus v.6.0 software (IPP; Media Cybernetics, Bethesda, MD, USA), and this protocol was repeated three times.

Analysis of the combined effects of the drugs

CompuSyn software (version 2.0; ComboSyn, Inc., Paramus, NJ, USA) was used to evaluate the synergistic effects of the combination of PHI and LY294002 using to the median-effect method (30). An MTT assay was performed to determine the fraction of cells affected (Fa). The combination index (CI) was calculated using CompuSyn. In this analysis, the combined effect was reported as synergistic, antagonistic or additive when the CI value was <1, >1 and 1, respectively.

Statistical analysis

Data were analyzed using SPSS statistical software (version 13.0; SPSS, Inc., Chicago, IL, USA). Results are presented as the mean ± standard deviation from multiple independent experiments using a homogeneity test for variance and test of normality. Results were evaluated by one-way analysis of variance between groups. Multiple comparison between the groups was performed using Student Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of PHI and LY294002 on HL-60 cell viability

PHI and LY294002 were identified to inhibit viability in HL-60 cells in a dose- and time-dependent manner. For instance, the viability of HL-60 cells was 97.1±2.1, 84.3±2.5, 57.3±2.1 and 36.2±2.4% when treated with PHI at 0, 10, 20 and 40 µmol/l, respectively, for 72 h (Fig. 1A); the half-maximal inhibitory concentration (IC50) was 26.19 µmol/l. Similarly, the viability of HL-60 cells was 98.3±1.1, 86.2±2, 64.2±2.3 and 48.7±2.0% when treated with LY294002 at 0, 10, 20 and 40 µmol/l, respectively, for 72 h (Fig. 1B); the IC50 was 36.44 µmol/l. The viability of HL-60 cells was 37.4±2.7% when treated with PHI and LY294002 in combination at 20 µmol/l each for 72 h. However, the viability was 57.3±2.5 and 64.2±2.3% when treated with PHI or LY294002, respectively, at 20 µmol/l separately for 72 h (Fig. 1C). The combination of PHI and LY294002 synergistically inhibited the viability of HL-60 cells. HL-60 cells were treated with 10, 15, 20, 30 and 40 µmol/l PHI and 10, 15, 20, 30 and 40 µmol/l LY294002 separately or in combination for 72 h (Fig. 1D). The CI values were 0.85635, 0.87545, 0.93326, 0.86816 and 0.73989 when treated with a combination of PHI and LY294002 at 10, 15, 20, 30 and 40 µmol/l (Fig. 1E). The combination of PHI and LY294002 at all concentrations exerted synergistic inhibitory effects on HL-60 cell viability.

Figure 1.

Figure 1.

Open in a new tab

PHI and LY294002 inhibit the viability of HL-60 cells. (A) Cell viability was inhibited at various concentrations of PHI in a dose- and time-dependent manner vs. untreated control. (B) Cell viability was inhibited at various concentrations of LY294002 in a dose- and time-dependent manner vs. untreated control. (C) PHI and LY294002 in combination exhibited a synergistic effect on HL-60 cell viability vs. PHI or LY294002 alone. (D) Dose-response curves of the single or combined drug treatments. (E) Fa-CI curve of PHI and LY294002 in combination revealing a synergistic effect with 10, 15, 20, 30 and 40 µmol/l (CI<1). The broken line at CI=1 represents the additive effect. *P<0.05, **P<0.01, ***P<0.001; Fa, affected fraction; CI, combination index.

Effects of PHI and LY294002 on apoptosis

Using flow cytometry, it was identified that the number of cells undergoing apoptosis was increased in a dose-dependent manner following exposure to PHI and/or LY294002 for 72 h. Exposure of HL-60 cells to PHI at 0, 10, 20 and 40 µmol/l for 72 h resulted in 1.28±0.43, 8.43±1.64, 15.40±2.48 and 26.4±3.22% apoptosis, respectively. Exposure of HL-60 cells to LY294002 at 0, 10, 20 and 40 µmol/l for 72 h resulted in 1.28±0.43, 5.43±1.34, 12.4±1.52 and 18.80±2.52% apoptosis, respectively. PHI and LY294002 in combination at 20 µmol/l each led to 52.7±4.51% apoptosis compared with 15.4±3.48% apoptosis for PHI alone and 12.4±1.52% apoptosis for LY294002 alone, each at 20 µmol/l (Fig. 2).

Figure 2.

Figure 2.

Open in a new tab

PHI and LY294002 induce apoptosis in HL-60 cells. Fluorescence signals from annexin V-FITC and PI are reported on the x-axis and y-axis, respectively. Four quadrants represent viable (lower left), necrotic (upper right), early apoptotic (lower right) and late apoptotic (upper right) cells. The rate of apoptosis of the cells is presented in the figure. (A) Apoptosis was increased gradually following treatment with PHI at 10, 20 and 40 µmol/l for 72 h in HL-60 cells vs. untreated control. (B) Apoptosis was increased gradually following treatment with LY294002 at 10, 20 and 40 µmol/l for 72 h in HL-60 cells vs. untreated control. (C) PHI and LY294002 in combination significantly increased apoptosis in HL-60 cells vs. PHI or LY294002 alone. *P<0.05, **P<0.01, ***P<0.001; FITC, fluorescein isothiocyanate; PI, propidium iodide; Q, quadrant.

LY294002 enhances the effect of PHI on acetylation of histone H3 and H4 in HL-60 cells

Treatment with PHI led to an accumulation of acetylated histone H3 and H4. However, LY294002 had no effect on it. The acetylation of histone H3 and histone H4 was increased markedly in dose- and time-dependent manner following exposure of HL-60 cells to PHI (Fig. 3A). Acetylated histone H3 was increased 1.65±0.08-, 2.96±0.14- and 5.21±0.24-fold by PHI at 10, 20 and 40 µmol/l, respectively, for 72 h compared with the control. Acetylated histone H4 was increased 1.32±0.06-, 2.55±0.12- and 3.92±0.18-fold by PHI at 10, 20 and 40 µmol/l, respectively, compared with the control. LY294002 was not able to alter the level of acetylation of histone H3 and histone H4. Acetylated histone H3 was increased 1.01±0.04-, 0.98±0.03- and 1.02±0.05-fold by LY249002 at 10, 20 and 40 µmol/l, respectively, for 72 h compared with the control. Acetylated histone H4 was increased 0.99±0.05-, 1.03±0.05- and 0.97±0.04-fold by LY249002 at 10, 20 and 40 µmol/l, respectively, for 72 h compared with the control (P>0.05; Fig. 3B). However, with in combination, LY294002 increased the effect that PHI exerted on histone H3 and histone H4 acetylation. Acetylated histone H3 and H4 were increased 2.96±0.14- and 2.55±0.12-fold by PHI alone, 3.11±0.16- and 2.83±0.13-fold by PHI and LY294002 in combination at 20 µmol/l each (Fig. 3C).

Figure 3.

Figure 3.

Open in a new tab

PHI, but not LY294002, promotes acetylation of histone H3 and histone H4 in HL-60 cells; however, PHI in combination with LY294002 enhances acetylation. (A) PHI at 10, 20 and 40 µmol/l for 72 h upregulated acetylated histone H3 and histone H4 in a concentration-dependent manner in HL-60 cells vs. untreated control. (B) LY294002 at 10, 20 or 40 µmol/l exhibited no effect on levels of acetylated histone H3 and histone H4 vs. untreated control. (C) PHI and LY294002 in combination increases the upregulation of acetylated histone H3 and histone H4 levels vs. PHI alone. *P<0.05, **P<0.01, ***P<0.001; Act-H, acetylated histone.

Synergistic effects of combined PHI and LY294002 treatment on inhibiting the PI3K/Akt signaling pathway in HL-60 cells

Levels of p-Akt, p-mTOR and p-p70S6K were decreased following exposure to PHI or LY294002. When PHI was combined with LY294002, the effect was more marked. p-Akt, p-mTOR and p-p70S6K levels were decreased following exposure to PHI or LY294002. Levels of p-Akt, p-mTOR and p-p70S6K were increased 0.92±0.06-, 0.90±0.05- and 0.89±0.05-fold, respectively, by PHI at 10 µmol/l, 0.55±0.03-, 0.71±0.04- and 0.65±0.03-fold, respectively, by PHI at 20 µmol/l, and 0.42±0.02-, 0.56±0.03- and 0.51±0.03-fold, respectively, by PHI at 40 µmol/l for 72 h, compared with the control (Fig. 4A). Similarly, the levels of p-Akt, p-mTOR and p-p70S6K were increased 0.87±0.03-, 0.81±0.04- and 0.79±0.04-fold, respectively, by LY294002 at 10 µmol/l, 0.51±0.03-, 0.62±0.04- and 0.54±0.03-fold, respectively, by LY294002 at 20 µmol/l, and 0.37±0.02-, 0.48±0.03- and 0.41±0.02-fold, respectively, by LY294002 at 40 µmol/l for 72 h, compared with the control (Fig. 4B). The levels of p-Akt, p-mTOR and p-p70S6K were increased 0.81±0.03-, 0.83±0.05- and 0.78±0.06-fold, respectively, by LY294002, respectively, at 20 µmol/l for 72 h, and 0.65±0.03-, 0.61±0.04- and 0.55±0.03-fold, respectively, by PHI at 20 µmol/l for 72 h compared with the control. However, levels of p-Akt, p-mTOR and p-p70S6K were increased 0.37±0.04-, 0.43±0.03- and 0.21±0.02-fold, respectively, by PHI and LY294002 in combination at 20 µmol/l each for 72 h compared with the control (Fig. 4C). The combination of PHI and LY294002 enhanced the effect on the protein levels of the PI3K/Akt signaling pathway.

Figure 4.

Figure 4.

Open in a new tab

PHI and LY294002 dephosphorylate proteins in the PI3K/Akt signaling pathway in HL-60 cells. (A) PHI dephosphorylated p-Akt, p-mTOR and p-p70S6K in a dose-dependent manner vs. untreated control. (B) LY294002 dephosphorylated p-Akt, p-mTOR and p-p70S6K in a dose-dependent manner vs. untreated control. (C) PHI and LY294002 in combination enhanced the dephosphorylation of p-Akt, p-mTOR and p-p70S6K vs. PHI or LY294002 alone. *P<0.05, **P<0.01, ***P<0.001.

Discussion

The results of the present study indicate that LY294002 and PHI induced cell apoptosis, decreased cell viability and dephosphorylated p-Akt, p-mTOR and p-p70S6K. Treatment with PHI led to an upregulation of histone acetylation. Our previous studies indicated that PHI induced cell apoptosis and inhibited cell viability in various tumor cell lines, including MOLT-4, PC3 and SMMC7721 cells (23,31,32). These results of these studies provide evidence of the underlying molecular mechanisms for the apoptotic effects of PHI, which modulates histone acetylation, histone methylation and DNA demethylation. The results are also consistent with the evidence that PHI dephosphorylated proteins in the PI3K/Akt signaling pathway, inactivated Akt and modulated histone acetylation in PC3 cells.

Activation of the PI3K/Akt signaling pathway results in disturbance of cell proliferation and apoptosis, providing a competitive proliferative advantage for tumor cells (4,33,34). It is clear that upregulation of the PI3K/Akt axis may be one of the major factors undermining successful antineoplastic treatment, thus leading to a poor prognosis in many types of cancer (35). Therefore, the PI3K/Akt pathway is an attractive target for the development of novel therapeutic strategies in patients with various types of tumor.

LY294002, a classical PI3K inhibitor, has been used in in vitro and in vivo studies on cancer cell lines in which it induces apoptosis and increases sensitivity to chemotherapeutic drugs (36–38). The results of the present study indicated that LY294002 may induce apoptosis and inhibit viability of HL-60 cells. It inhibits the PI3K/Akt signaling pathway by dephosphorylating p-Akt, p-mTOR and p-p70S6K.

In the present study, it was confirmed for the first time, to the best of our knowledge, that a combination of LY294002 and PHI exerts synergistic effects on inducing apoptosis and inhibiting viability of HL-60 cells. The results indicated that PHI or LY294002 resulted in an increase in the apoptotic rate and inhibition of cell viability in a dose-dependent manner. PHI and LY294002 in combination at 20 µmol/l each exhibited a synergistic effect with a significantly increased apoptosis rate. Treatment with PHI or LY294002 separately at 20 µmol/l for 72 h led to cell viability of 57.3±2.5 and 64.2±2.3%, respectively, compared with the control. PHI and LY294002 in combination at 20 µmol/l each exhibited a synergistic effect with a significantly increased inhibition of cell viability. Investigation into the underlying molecular mechanism indicated that PHI induced an accumulation of acetylated histone H3 and histone H4 in HL-60 cells; however, LY294002 exhibited no effect on histone acetylation. However, upregulation of acetylated histone H3 and histone H4 was increased by PHI in combination with LY294002 compared with PHI alone. These results indicated that LY294002 may enhance the effect of PHI on histone acetylation. PHI and LY294002 each dephosphorylated p-Akt; in combination, they resulted in a synergistic effect, dephosphorylating p-Akt further.

Akt synergistically enhanced the activity of histone acetyltransferases (HATs), inducing p300, and the increasing the binding capacity with the HAT p300/cyclic adenosine 5′-monophosphate-response element-binding protein-binding protein (CBP)-associated factor (39). Rapamycin inhibition of the mTOR signaling pathway may lead to the release of the oncogene Esa1 from the ribosomal protein gene promoter and lead to histone H4 deacetylation, thereby affecting gene expression (40). Resistance to histone deacetylase inhibitors in non-small cell lung cancer is mediated in part through the activation of nuclear factor-κβ through the phosphatidylinositol 3-kinase/Akt-dependent pathway (41). A number of studies (42–44) have indicated that the dynamic changes of histone modification may regulate mTOR signaling pathway protein kinase activity. However, the underlying molecular mechanism remains unknown. A study by Gan and Zhang (45) identified that the activation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and Akt phosphorylation was downregulated by trichostatin A (TSA) treatment. This study demonstrated that downregulation of Akt phosphorylation induced by TSA may be mediated by PTEN small interfering RNA. It has been identified that the phosphorylation of Akt at Ser1834 enhances the transcriptional activity of p300 by increasing promoter recruitment and histone acetylation (39). Chromatin immunoprecipitation assays revealed that CBPs and nuclear factor erythroid 2-related factor (Nrf2) recruitment to the antioxidant-response element (ARE) and broad complex-tramtrack-bric-a-brac and cap‘n’collar homology 1 release were inhibited by LY294002, along with the partial inhibition of Nrf2 nuclear accumulation (46). Furthermore, acetylation of histone H3 at Lys9 and Lys18, and deacetylation histone H3 at Lys14 were associated with PI3K-dependent ARE activation. Apoptosis induced by doxorubicin, an inhibitor of the PTEN signaling pathway, was enhanced by TSA. Furthermore, TSA promoted early growth response protein 1 (Egr-1) expression, which is the major transcription factor of PTEN, and this resulted in upregulation of PTEN expression, which consequently potentiated apoptosis (47). HAT p300 was able to synergistically activate PTEN transcription with Egr-1, implicating the role of histone acetylation in the regulation of PTEN expression.

The results of the present study suggest that a combination of PHI and LY294002 may be a novel treatment for acute leukemia.

Acknowledgements

The present study was partly supported by a grant-in-aid from the Foundation of Science and Technology of Zhangzhou, Fujian, China (grant no. Z07014), the Foundation of Science and Technology of Fujian Medical University, Fujian, China (grant no. FZS08018), the Science Research Foundation of the Ministry of Health, and United Fujian Provincial Health, and Education Project for Tackling Key Research, China (grant no. WKJ2008-2-55).

Glossary

Abbreviations

PHI

phenylhexyl isothiocyanate

AML

acute myeloid leukemia

DMSO

dimethyl sulfoxide

p-Akt

phosphorylated protein kinase B

p-mTOR

phosphorylated mammalian target of rapamycin

p-p70S6K

phosphorylated ribosomal protein S6 kinase

HAT

histone acetyltransferase

PTEN

phosphatase and tensin homolog deleted on chromosome 10

TSA

trichostatin A; V-fluorescein isothiocyanate FITC

CI

combination index

Fa

affected fraction

References

  • 1.Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051–1062. doi: 10.1056/NEJM199909303411407. [DOI] [PubMed] [Google Scholar]
  • 2.Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J Clin Oncol. 1989;7:1260–1267. doi: 10.1200/JCO.1989.7.9.1260. [DOI] [PubMed] [Google Scholar]
  • 3.Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Childrens cancer group study. J Clin Oncol. 1994;12:2367–2377. doi: 10.1200/JCO.1994.12.11.2367. [DOI] [PubMed] [Google Scholar]
  • 4.Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86. doi: 10.1016/S0065-230X(05)94002-5. [DOI] [PubMed] [Google Scholar]
  • 5.Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: Direct evidence of PI3K activation. Leukemia. 2004;18:1438–1440. doi: 10.1038/sj.leu.2403402. [DOI] [PubMed] [Google Scholar]
  • 6.Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS, Ko YW. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia. 2003;17:995–997. doi: 10.1038/sj.leu.2402874. [DOI] [PubMed] [Google Scholar]
  • 7.Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 Kinase activation. Blood. 2003;102:972–980. doi: 10.1182/blood-2002-11-3429. [DOI] [PubMed] [Google Scholar]
  • 8.Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004;18:267–275. doi: 10.1038/sj.leu.2403220. [DOI] [PubMed] [Google Scholar]
  • 9.Stauffer F, Holzer P, García-Echeverria C. Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents. 2005;5:449–462. doi: 10.2174/1568011054866937. [DOI] [PubMed] [Google Scholar]
  • 10.Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci. 2004;29:233–242. doi: 10.1016/j.tibs.2004.03.006. [DOI] [PubMed] [Google Scholar]
  • 11.Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta. 2004;1697:3–16. doi: 10.1016/j.bbapap.2003.11.009. [DOI] [PubMed] [Google Scholar]
  • 12.Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014;16:378–386. doi: 10.4103/1008-682X.122876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang P, Liu N, Pang Q, Qu C, Wang B, Guo H. PI3K/AKT signaling pathway in the regulation of non-small cell lung cancer radiosensitivity after hypofractionated radiation therapy. Int J Radia Oncol Biol Physics. 2012;84:S670. doi: 10.1016/j.ijrobp.2012.07.1790. (Suppl) [DOI] [Google Scholar]
  • 14.Roche S, Koegl M, Courtneidge SA. The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors. Proc Natl Acad Sci USA. 1994;91:9185–9189. doi: 10.1073/pnas.91.19.9185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Shivakrupa R, Bernstein A, Watring N, Linnekin D. Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 2003;63:4412–4419. [PubMed] [Google Scholar]
  • 16.Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002;1:989–997. [PubMed] [Google Scholar]
  • 17.Hu H, Jiang C, Li G, Lü J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis. 2005;26:1374–1381. doi: 10.1093/carcin/bgi094. [DOI] [PubMed] [Google Scholar]
  • 18.Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 1995;15:1135–1139. [PubMed] [Google Scholar]
  • 19.Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002) Clin Cancer Res. 2000;6:880–886. [PubMed] [Google Scholar]
  • 20.Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res. 2002;8:1957–1963. [PubMed] [Google Scholar]
  • 21.Minarini A, Milelli A, Fimognari C, Simoni E, Turrini E, Tumiatti V. Exploring the effects of isothiocyanates on chemotherapeutic drugs. Expert Opin Drug Metab Toxicol. 2014;10:25–38. doi: 10.1517/17425255.2013.843668. [DOI] [PubMed] [Google Scholar]
  • 22.Cavell BE, Syed Alwi SS, Donlevy A, Packham G. Anti-angiogenic effects of dietary isothiocyanates: Mechanisms of action and implications for human health. Biochem Pharmacol. 2011;81:327–336. doi: 10.1016/j.bcp.2010.10.005. [DOI] [PubMed] [Google Scholar]
  • 23.Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D, Chiao JW. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 2006;28:1287–1293. [PubMed] [Google Scholar]
  • 24.Xiao L, Huang Y, Zhen R, Chiao JW, Liu D, Ma X. Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol. 2010;123:71–76. doi: 10.1159/000264628. [DOI] [PubMed] [Google Scholar]
  • 25.Huang YQ, Ma XD, Zhen RJ, Chiao JW, Liu DL. Experiment study of PHI on histone methylation and acetylation in Molt-4 cells. Zhonghua Xue Ye Xue Za Zhi. 2007;28:612–615. (In Chinese) [PubMed] [Google Scholar]
  • 26.Jiang S, Ma X, Huang Y, Xu Y, Zheng R, Chiao JW. Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol. 2010;3:48. doi: 10.1186/1756-8722-3-48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zou Y, Ma X, Huang Y, Hong L, Chiao JW. Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol. 2012;5:36. doi: 10.1186/1756-8722-5-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia. 2008;22:1106–1116. doi: 10.1038/leu.2008.79. [DOI] [PubMed] [Google Scholar]
  • 29.Wang L, Liu D, Ahmed T, Chung FL, Conaway C, Chiao JW. Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol. 2004;24:187–192. [PubMed] [Google Scholar]
  • 30.Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681. doi: 10.1124/pr.58.3.10. [DOI] [PubMed] [Google Scholar]
  • 31.Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res. 2006;26:1225–1230. [PubMed] [Google Scholar]
  • 32.Lai YD, Ma XD, Huang YQ, Xu XN, Wang XZ, Chiao DJ, Liu D. Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate. Zhonghua Zhong Liu Za Zhi. 2010;32:804–807. (In Chinese) [PubMed] [Google Scholar]
  • 33.Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 2004;9:667–676. doi: 10.1023/B:APPT.0000045801.15585.dd. [DOI] [PubMed] [Google Scholar]
  • 34.Zhuang Z, Ma X, Huang Y, Zheng Z, Zheng Y, Jiang S. Study on histone acetylation modulation and Akt signaling pathway inhibition by phenyhexyle isothiocyanate in prostate cancer PC3 cell line. Chin J Urol. 2010;31:707–709. [Google Scholar]
  • 35.Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005;10:975–987. doi: 10.2741/1592. [DOI] [PubMed] [Google Scholar]
  • 36.West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5:234–248. doi: 10.1016/S1368-7646(02)00120-6. [DOI] [PubMed] [Google Scholar]
  • 37.Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM, Cocco L. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol. 2005;20:239–252. doi: 10.14670/HH-20.239. [DOI] [PubMed] [Google Scholar]
  • 38.Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 2003;4:257–262. doi: 10.1016/S1535-6108(03)00248-4. [DOI] [PubMed] [Google Scholar]
  • 39.Huang WC, Chen CC. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol. 2005;25:6592–6602. doi: 10.1128/MCB.25.15.6592-6602.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Rohde JR, Cardenas ME. The tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. Mol Cell Biol. 2003;23:629–635. doi: 10.1128/MCB.23.2.629-635.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Denlinger CE, Rundall BK, Jones DR. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J Thorac Cardiovasc Surg. 2005;130:1422–1429. doi: 10.1016/j.jtcvs.2005.06.051. [DOI] [PubMed] [Google Scholar]
  • 42.Wang X, Sun DF, Fang JY. Research advances on the relationship of PI3-kinase/Akt/mTOR pathway and epigenetic modification. Yi Chuan. 2006;28:1585–1590. doi: 10.1360/yc-006-1585. (In Chinese) [DOI] [PubMed] [Google Scholar]
  • 43.Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li T, Hattori N, Wang D, Du Y, Song B, et al. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy. 2015;11:2309–2322. doi: 10.1080/15548627.2015.1117734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia. 2008;22:2159–2568. doi: 10.1038/leu.2008.243. [DOI] [PubMed] [Google Scholar]
  • 45.Gan YH, Zhang S. PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol. 2009;45:e150–e154. doi: 10.1016/j.oraloncology.2009.05.563. [DOI] [PubMed] [Google Scholar]
  • 46.Sakamoto K, Iwasaki K, Sugiyama H, Tsuji Y. Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell. 2009;20:1606–1617. doi: 10.1091/mbc.E08-07-0762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, Huang B. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer. 2007;109:1676–1688. doi: 10.1002/cncr.22585. [DOI] [PubMed] [Google Scholar]

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES